CellProthera publishes Phase I/IIb trial in JACC: Heart Failure

CellProthera announced that the results from its EXCELLENT Phase I/IIb trial of ProtheraCytes® have now been published in JACC: Heart Failure, offering the first peer-reviewed evidence on the therapy’s safety and feasibility in patients with severe heart failure following myocardial infarction. The randomized, open-label study enrolled 49 patients across sites in France and the UK. […] The post CellProthera publishes Phase I/IIb trial in JACC: Heart Failure appeared first on Longevity.Technology.